The hedge fund’s shares of CHS are valued at $26.63 million. CHS makes up about 15.09 percent of Accipiter’s portfolio, according to Trade Calls.
Other hedge funds, including D. E. Shaw, also upped their stakes in CHS in the most recent quarter.
More articles on healthcare finance:
Should providers become payers? 4 key considerations
Calif. denies Saint Agnes Medical Center’s request to lower charity care minimum
AHA urges CMS to delay site-neutral payment policy
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
